Longitudinal SV2A and MRI in Premanifest HD

Recruiting

LEARN MORE

HERE

SPONSOR

Universitaire Ziekenhuizen KU Leuven

PARTICIPANTS

35

The investigators will include late premanifest HD mutations carriers and matched healthy controls.

All subjects will undergo a clinical examination, with comprehensive assessment of motor and non-motor symptoms. Including imaging evaluation using Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 18F-SynVesT-1. And magnetic resonance imaging(MRI) of brain volume at baseline(initial visit) and 2 years

Ages Eligible
for Study:

20 Years to 75 Years

(Adult,  Older Adult )

Sexes Eligible
for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria

 

  • Capacity to understand the informed consent form.

  • HD mutation carriers:

    • HTT (CAG)n ≥ 40
    • HD-ISS < 2
    • CAP100 score > 70

Exclusion Criteria

 

  • neuropsychiatric diseases (other than HD for HD mutation carriers)
  • major internal medical diseases
  • white matter lesion load on FLAIR Fazekas score 2 or higher or other relevant MRI abnormalities
  • history of alcohol abuse or current alcohol abuse (chronic use of more than 15 units per week) or drug abuse
  • contraindications for MR
  • pregnancy
  • previous participation in other research studies involving ionizing radiation with more than 1 mSv in the previous 12 months.

LOCATIONS

BELGIUM

TRIAL SITE:
Universitaire Ziekenhuizen KU Leuven

Address: Leuven, Belgium

CONTACT: Wim Vandenberghe, MD, PhD

Email: http://wim.vandenberghe@uzleuven

Recruiting